Your browser doesn't support javascript.
loading
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.
Pantaleo, Giuseppe; Janes, Holly; Karuna, Shelly; Grant, Shannon; Ouedraogo, G Laissa; Allen, Mary; Tomaras, Georgia D; Frahm, Nicole; Montefiori, David C; Ferrari, Guido; Ding, Song; Lee, Carter; Robb, Merlin L; Esteban, Mariano; Wagner, Ralf; Bart, Pierre-Alexandre; Rettby, Nils; McElrath, M Juliana; Gilbert, Peter B; Kublin, James G; Corey, Lawrence.
Afiliação
  • Pantaleo G; Service of Immunology and Allergy, and Swiss Vaccine Research Institute, Lausanne University Hospital, Lausanne, Switzerland. Electronic address: giuseppe.pantaleo@chuv.ch.
  • Janes H; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Karuna S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Grant S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Ouedraogo GL; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA; US Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Allen M; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Tomaras GD; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Frahm N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA.
  • Montefiori DC; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Ferrari G; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Ding S; EuroVacc Foundation, Lausanne, Switzerland.
  • Lee C; Global Solutions for Infectious Diseases, South San Francisco, CA, USA.
  • Robb ML; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
  • Esteban M; Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
  • Wagner R; Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
  • Bart PA; Service of Immunology and Allergy, and Swiss Vaccine Research Institute, Lausanne University Hospital, Lausanne, Switzerland.
  • Rettby N; Service of Immunology and Allergy, and Swiss Vaccine Research Institute, Lausanne University Hospital, Lausanne, Switzerland.
  • McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Lancet HIV ; 6(11): e737-e749, 2019 11.
Article em En | MEDLINE | ID: mdl-31601541
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / Proteína gp120 do Envelope de HIV / Infecções por HIV / Vacinas contra a AIDS / Vacinas de DNA / Anticorpos Neutralizantes Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet HIV Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / Proteína gp120 do Envelope de HIV / Infecções por HIV / Vacinas contra a AIDS / Vacinas de DNA / Anticorpos Neutralizantes Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet HIV Ano de publicação: 2019 Tipo de documento: Article